Vevo 2100 Ultrasound System

Vevo 2100 超声系统

• 批准号: 8246980
• 负责人: LISA M. COUSSENS
• 金额: $ 40.4万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-06-01 至 2013-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8246980
• 关键词: Abdomen; Address; Animals; Biology; Blood Vessels; Blood flow; California; Characteristics; Communities; Development; Diagnosis; Disease; Embryonic Development; Foundations; Funding; Heterogeneity; Image; Imagery; Injection of therapeutic agent; Left; Life; Location; Longitudinal Studies; MRI Scans; Maintenance; Malignant Neoplasms; Measures; Mesothelioma; Mission; Modeling; Monitor; Mus; Normal tissue morphology; Organ; Patients; Physiologic pulse; Positron-Emission Tomography; Process; Public Health; Relative (related person); Research; Research Personnel; Resolution; San Francisco; Speed; Structure; System; Therapeutic Intervention; Time; Tissues; Tumor Angiogenesis; Ultrasonography; United States National Institutes of Health; Universities; Vascular Endothelial Growth Factor Receptor; X-Ray Computed Tomography; effective therapy; high standard; human disease; imaging modality; implantation; insight; lung development; mouse model; pancreatic neoplasm; research and development; response; tumor

DESCRIPTION (provided by applicant): Mouse studies offer tremendous insight into the development of normal tissues and of diseased tissues including cancer. The ability to image mice repeatedly and non-invasively is necessary for understanding the course of therapeutic interventions and to minimize the use of mice in experimentation. Ultrasound imaging is the accepted standard for high resolution imaging, offering the ability for repeated, inexpensive, investigator-operated, real-time monitoring of mice. The many NIH-funded investigators using mice at the University of California San Francisco Parnassus have relied on a Vevo 770 ultrasound small animal imager that will be moved to the newly opened research campus at Mission Bay. This planned move will leave the investigators without the ability for noninvasive imaging. Because the mice are behind a barrier, longitudinal studies by other imaging modalities such as MRI, CT or PET scanning are not possible due to their locations outside the barrier facility. Thus, these investigators have joined to apply for a new ultrasound and, in the process, have decided to take advantage of the higher resolution, greater depth of field and capabilities for vascular analysis of the new Vevo 2100. The multiple major users on this application are diverse, but are united by the desire to carry out longitudinal, non-invasive studies in mice. The high resolution imaging will enhance the ability of researchers to diagnose tumor development de novo, localize tissues for accurate injection, and confirm early implantation and monitor embryonic development in models of lung development. The increased depth of focus will enable visualization of organs throughout the abdomen, needed for detecting and monitoring pancreatic tumors and mesothelioma. The Doppler components (pulsed wave and power) will permit visualization of the vasculature of a tissue and its change over time. The 3D capability will rapidly and accurately measure the volume of a defined structure, such as a tumor, and will display the heterogeneity of tissues so that different regions can be analyzed separately. Finally, the contrast enhancement features expand the capabilities of the ultrasound: with non-targeted synthetic bubbles, the Vevo 2100 can quantify relative blood flow to an organ; with synthetic bubbles targeted to various endothelial targets such as VEGF receptor, the Vevo 2100 can identify relative expression of the targets characteristic of tumor angiogenesis. A Vevo 2100 Small Animal Imager would immediately address the needs of the NIH- funded investigators included here as major users and would enhance opportunities for all mouse users of the barrier facility. With the added support of the Simmons Mesothelioma Foundation to provide long-term maintenance, this state-of-the-art small animal imager will enhance research for the diverse community of those studying mice at UCSF. Relevance to Public Health: Mouse models of human disease are essential for understanding the underlying biology of disease and for developing effective therapies. The translational value of studies will be greatly enhanced by the ability to image living mice non-invasively and repetitively over time. A small animal ultrasound imaging system will allow investigators to monitor mice used in their research for the development of conditions and the response to therapy, thereby increasing efficiency, reducing the number of mice needed, and speeding the development of potential treatments for patients.

描述（由申请人提供）：小鼠研究为正常组织和包括癌症在内的病变组织的发育提供了巨大的洞察力。重复和非侵入性地对小鼠成像的能力对于理解治疗干预的过程和最小化实验中小鼠的使用是必要的。超声成像是高分辨率成像的公认标准，提供了对小鼠进行重复的、廉价的、自动化操作的实时监测的能力。加州大学弗朗西斯科分校帕纳苏斯分校的许多NIH资助的研究人员使用小鼠，他们依赖于Vevo 770超声小动物成像仪，该成像仪将被转移到使命湾新开放的研究园区。这一计划中的举措将使研究人员无法进行非侵入性成像。由于小鼠位于屏障后面，因此无法通过其他成像方式（如MRI、CT或PET扫描）进行纵向研究，因为它们位于屏障设施之外。因此，这些研究人员已经加入申请新的超声，并在此过程中，决定利用新Vevo 2100的更高分辨率，更大的景深和血管分析能力。该应用程序的多个主要用户是不同的，但都希望在小鼠中进行纵向，非侵入性研究。高分辨率成像将增强研究人员从头诊断肿瘤发展，定位组织以进行准确注射，并确认早期植入和监测肺发育模型中的胚胎发育的能力。增加的焦点深度将使整个腹部的器官可视化，这是检测和监测胰腺肿瘤和间皮瘤所需的。多普勒组件（脉冲波和功率）将允许可视化组织的脉管系统及其随时间的变化。3D功能将快速准确地测量定义结构（如肿瘤）的体积，并显示组织的异质性，以便可以单独分析不同区域。最后， 对比增强功能扩展了超声的能力：对于非靶向合成气泡，Vevo 2100可以量化流向器官的相对血流;对于靶向各种内皮靶点（如VEGF受体）的合成气泡，Vevo 2100可以识别肿瘤血管生成特征性靶点的相对表达。Vevo 2100小动物成像仪将立即满足NIH资助的研究人员的需求，包括在这里作为主要用户，并将增加屏障设施的所有鼠标用户的机会。随着西蒙斯间皮瘤基金会的额外支持，以提供长期维护，这种最先进的小动物成像仪将加强研究为那些在加州大学旧金山分校研究小鼠的多样化社区。 与公共卫生的相关性：人类疾病的小鼠模型对于理解疾病的潜在生物学和开发有效的治疗方法至关重要。随着时间的推移，非侵入性和重复性地对活体小鼠进行成像的能力将大大提高研究的转化价值。小动物超声成像系统将使研究人员能够监测他们研究中使用的小鼠的病情发展和对治疗的反应，从而提高效率，减少所需小鼠的数量，并加快为患者开发潜在治疗方法。